Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ravidasvir Tablet Formulations in Healthy Volunteers
NCT03602300Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ravidasvir in hepatitis C (HCV) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 1 more. Started Jun 2018; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03602300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602300.